| Previous Close | 44.16 |
| Open | 44.23 |
| Bid | 0.00 x |
| Ask | 0.00 x |
| Day's Range | 44.10 - 44.38 |
| 52 Week Range | 37.20 - 45.58 |
| Volume | 1,981,144 |
| Avg. Volume | 3,001,470 |
| Market Cap | 107.6B |
| Beta | 1.06 |
| PE Ratio (TTM) | 51.26 |
| EPS (TTM) | 0.86 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Dividend & Yield | 1.95 (4.48%) |
| Ex-Dividend Date | 2017-05-10 |
| 1y Target Est | 47.55 |
Reuters•2 days agoGSK's new CEO aims to divest sports nutrition brand: sources
GlaxoSmithKline Plc's new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller products with plans to divest its MaxiNutrition sports nutrition brand, two people familiar with the matter said on Thursday. GSK bought the business, which makes protein bars, drinks and powders, for 162 million pounds ($205 million) in 2010 under previous CEO Andrew Witty. The original acquisition was seen as complementing GSK's Lucozade sports drinks.
- Zacks•2 days ago
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.
- CNBC•2 days ago
Early movers: ORCL, HAIN, ACN, SCS, ATUS, NVS, GSK & more
These are the stocks posting the largest moves before the bell.
